Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PF-07832837

Other · developed by PFIZER

Phase 1 Most advanced trial
PFE Developer

What is PF-07832837?

PF-07832837 is an investigational agent studied in healthy participants and in atopic dermatitis, given at escalating doses.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Dermatology
Developer
PFIZER (PFE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Atopic DermatitisHealthy Participants

More from PFIZER

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind PF-07832837

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.